Biomarin Pharmaceutical (BMRN) Goodwill (2009 - 2026)

Biomarin Pharmaceutical has disclosed Goodwill across 18 years of filings, most recently posting $196.2 million for Q1 2026.

• Quarterly Goodwill changed 0.0% year-over-year to $196.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $196.2 million (changed 0.0% YoY) and the FY2025 annual result came in at $196.2 million, changed 0.0% from the prior year.
• Goodwill was little changed at $196.2 million in Q1 2026, from $196.2 million in the prior quarter.
• Over five years, Goodwill peaked at $196.2 million in Q1 2022 and troughed at $196.2 million in Q1 2022.
• A 5-year average of $196.2 million and a median of $196.2 million in 2022 frame the typical range for Goodwill.
• Biggest YoY gain for Goodwill was 0.0% in 2022; the steepest drop was 0.0% in 2022.
• Tracing BMRN's Goodwill over 5 years: stood at $196.2 million in 2022, then changed by 0.0% to $196.2 million in 2023, then changed by 0.0% to $196.2 million in 2024, then changed by 0.0% to $196.2 million in 2025, then changed by 0.0% to $196.2 million in 2026.
• Business Quant data shows BMRN's Goodwill at $196.2 million in Q1 2026, $196.2 million in Q4 2025, and $196.2 million in Q3 2025.